Focal segmental glomerulosclerosis 4, susceptibility to
MONDO:0012931Any focal segmental glomerulosclerosis in which the cause of the disease is a mutation in the APOL1 gene.
Also known as: APOL1 focal segmental glomerulosclerosis, focal segmental glomerulosclerosis 4, susceptibility to, focal segmental glomerulosclerosis caused by mutation in APOL1, glomerulosclerosis, focal segmental, 4, susceptibility to, FSGS4, end-stage renal disease, nondiabetic, susceptibility to, susceptibility to focal segmental glomerulosclerosis 4
11 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsBroader categories
-
Could a common arthritis drug help black patients with kidney disease?
Disease control CompletedThis study tested whether baricitinib, a drug used for arthritis, can safely reduce high protein levels in the urine of African American adults with a specific genetic form of kidney disease (APOL1). Eight participants took the drug to see if it lowered their urine protein and pr…
Phase: PHASE2 • Sponsor: Duke University • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New drug targets genetic kidney disease in small trial
Disease control CompletedThis study tested a new drug called VX-147 in 16 adults with a specific genetic form of kidney disease (APOL1-mediated FSGS). The goal was to see if the drug could reduce protein in the urine, a sign of kidney damage, and to check its safety. The drug is taken by mouth and aims t…
Phase: PHASE2 • Sponsor: Vertex Pharmaceuticals Incorporated • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC